Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of IBI3003 in Relapsed or Refractory Multiple Myeloma
NCT06083207Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of IBI3003 in multiple myeloma (MM), sponsored by Innovent Biologics. Started Jul 2024; status: recruiting.
02
Drugs
IBI3003
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06083207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083207.